Syros Pharmaceuticals (NASDAQ:SYRS) Share Price Crosses Below 50 Day Moving Average of $5.25

Syros Pharmaceuticals, Inc. (NASDAQ:SYRSGet Free Report) shares crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $5.25 and traded as low as $4.99. Syros Pharmaceuticals shares last traded at $5.00, with a volume of 68,625 shares.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on SYRS shares. StockNews.com raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 15th. Piper Sandler restated an “overweight” rating and set a $13.00 target price on shares of Syros Pharmaceuticals in a report on Wednesday, April 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Syros Pharmaceuticals in a research note on Wednesday, May 15th.

Check Out Our Latest Research Report on Syros Pharmaceuticals

Syros Pharmaceuticals Price Performance

The company has a quick ratio of 3.01, a current ratio of 3.01 and a debt-to-equity ratio of 1.97. The business has a fifty day moving average of $5.25 and a 200 day moving average of $5.72. The firm has a market cap of $133.65 million, a P/E ratio of -1.00 and a beta of 1.75.

Syros Pharmaceuticals (NASDAQ:SYRSGet Free Report) last posted its earnings results on Tuesday, May 14th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.10. Syros Pharmaceuticals had a negative return on equity of 395.36% and a negative net margin of 1,656.34%. During the same quarter last year, the firm posted ($0.85) EPS. On average, sell-side analysts anticipate that Syros Pharmaceuticals, Inc. will post -3.19 earnings per share for the current year.

Institutional Trading of Syros Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of SYRS. Virtu Financial LLC acquired a new position in Syros Pharmaceuticals in the 1st quarter valued at about $64,000. Acadian Asset Management LLC acquired a new position in shares of Syros Pharmaceuticals in the first quarter valued at approximately $91,000. Assenagon Asset Management S.A. increased its stake in shares of Syros Pharmaceuticals by 142.2% during the third quarter. Assenagon Asset Management S.A. now owns 25,130 shares of the company’s stock worth $99,000 after purchasing an additional 14,754 shares during the period. Kennedy Capital Management LLC bought a new position in shares of Syros Pharmaceuticals during the first quarter worth approximately $2,166,000. Finally, Opaleye Management Inc. acquired a new stake in Syros Pharmaceuticals during the 4th quarter worth approximately $2,799,000. Institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Company Profile

(Get Free Report)

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.

Further Reading

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.